Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Melinda J, Gooderham"'
Autor:
Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Michael J. Cork, Lawrence F. Eichenfield, Eric L. Simpson, Athanasios Tsianakas, Urs Kerkmann, Claire Feeney, William Romero
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2285-2296 (2024)
Abstract Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3
Externí odkaz:
https://doaj.org/article/9fab2eaae3014f6bb0a226938e458120
Autor:
Leon H. Kircik, Linda Stein Gold, Michael Gold, Jonathan S. Weiss, Julie C. Harper, James Q. Del Rosso, Christopher G. Bunick, Neal Bhatia, Emil A. Tanghetti, Lawrence F. Eichenfield, Hilary Baldwin, Zoe D. Draelos, Valerie D. Callender, George Han, Melinda J. Gooderham, Neil Sadick, Mary P. Lupo, Edward (Ted) Lain, William Philip Werschler
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1211-1227 (2024)
Abstract Introduction A three-pronged approach to acne treatment combining an antibiotic, antimicrobial, and retinoid may be more efficacious than single/double treatments while potentially reducing antibiotic resistance. This study evaluated the eff
Externí odkaz:
https://doaj.org/article/3acfbfb6dfc943fb93eb738feae1be47
Autor:
Melinda J. Gooderham, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, Mahreen Ameen, Eric L. Simpson, Gary Chan, Pinaki Biswas, Wing S. Chiu, Melissa Watkins
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 753-763 (2023)
Abstract Background Patients with moderate‐to‐severe atopic dermatitis (AD) refractory to topical therapy might require treatment with systemic therapies, including biologics. Objectives To assess the efficacy and safety of abrocitinib monotherap
Externí odkaz:
https://doaj.org/article/f7c8551174694873b56769ea8f6eb795
Autor:
Melinda J. Gooderham, Andrew E. Pink, Eric L. Simpson, Jonathan I. Silverberg, Erman Güler, Melissa Watkins
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 9, Pp 1893-1907 (2023)
Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg
Externí odkaz:
https://doaj.org/article/910ab250dacb46cba12498d99a103afa
Autor:
Kim A. Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J. Hotte, Jennifer R. Beecker, Mark G. Kirchhof, Irina Turchin, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles W. Lynde, Vimal H. Prajapati, Ronald B. Vender
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 867-889 (2023)
Abstract Background Patients with treated solid tumours (TSTs) are a highly heterogeneous population at an increased risk for malignancy compared with the general population. When treating psoriasis in patients with a history of TSTs, clinicians are
Externí odkaz:
https://doaj.org/article/062de13938e141a89117a95d3fedf09a
Autor:
Kim A. Papp, Jennifer Beecker, Curtis Cooper, Mark G. Kirchhof, Anton L. Pozniak, Juergen K. Rockstroh, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Charles W. Lynde, Catherine Maari, Yves Poulin, Ronald B. Vender, Sharon L. Walmsley
Publikováno v:
Dermatology and Therapy, Vol 12, Iss 5, Pp 1073-1089 (2022)
Abstract Background People living with human immunodeficiency virus (PLHIV) have a similar prevalence of psoriasis as the general population, though incidence and severity correlate with HIV viral load. Adequately treating HIV early renders the infec
Externí odkaz:
https://doaj.org/article/a8e3ca70c7c04b0ea1cd9216fab2a8e2
Autor:
Kim A. Papp, Barbara Melosky, Sandeep Sehdev, Sebastien J. Hotte, Jennifer R. Beecker, Mark G. Kirchhof, Irina Turchin, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles W. Lynde, Vimal H. Prajapati, Ronald B. Vender
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1889-1890 (2023)
Externí odkaz:
https://doaj.org/article/7d190fe2e54149f09fa4e20f27e10e09
Autor:
Kim A. Papp, Jennifer Beecker, Curtis Cooper, Mark G. Kirchhof, Anton L. Pozniak, Juergen K. Rockstroh, Jan P. Dutz, Melinda J. Gooderham, Robert Gniadecki, Chih-ho Hong, Charles W. Lynde, Catherine Maari, Yves Poulin, Ronald B. Vender, Sharon L. Walmsley
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1891-1892 (2023)
Externí odkaz:
https://doaj.org/article/df8a010ddfd24de28758f2c5760c3302
Autor:
Erika L. Crowley, Melinda J. Gooderham
Publikováno v:
Pharmaceutics, Vol 16, Iss 1, p 23 (2023)
Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase-4 (PDE4) inhibitors are emerging with expanding options. PDE4 inhibitors play a pivota
Externí odkaz:
https://doaj.org/article/1e0e3b8c76b145bf8f47f9b2bb9ad716
Autor:
Bohmyi Choi, BSc, Marcus G. Tan, MD, Melinda J. Gooderham, MD, MSc, Jennifer Beecker, MD, FRCPC, CCFP-EM, DABD
Publikováno v:
JAAD Case Reports, Vol 16, Iss , Pp 149-151 (2021)
Externí odkaz:
https://doaj.org/article/e9c50ec5bdbb41a099c71820c7d2906a